Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern

INTRODUCTION

In vitro evaluation of drug effects on hERG K(+) channels is a valuable tool for identifying potential proarrhythmic side effects in drug safety testing. Patch-clamp recording of hERG K(+) current in mammalian cells can accurately evaluate drug effects, but the methodology has not been standardized, and results vary widely. Our objective was to evaluate two potential sources of variability: the temperature at which recordings are performed and the voltage pulse protocol used to activate hERG K(+) channels expressed in HEK293 cells.

METHODS

A panel of 15 drugs that spanned a broad range of potency for hERG inhibition and pharmacological class was evaluated at both room and near-physiological temperatures using several patch-clamp voltage protocols. Concentration-response analysis was performed with three stimulus protocols: 0.5- and 2-s step pulses, or a step-ramp pattern.

RESULTS

Block by 2 of the 15 drugs tested, d,l-sotalol (antiarrhythmic) and erythromycin (antibiotic), was markedly temperature sensitive. hERG inhibition measured using a 2-s step-pulse protocol underestimated erythromycin potency compared with results obtained with a step-ramp protocol. Using conservative acceptance criteria and the step-ramp protocol, the IC(50) values for hERG block differed by less than twofold for 15 drugs.

DISCUSSION

Data obtained at near-physiological temperatures using a step-ramp pattern are highly repeatable and provide a conservative safety evaluation of hERG inhibition.

Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells

INTRODUCTION: Non-clinical evaluation of a medication's potential to induce cardiac toxicity is recommended by regulatory agencies. 4-Aminopyridine (fampridine) is a potassium channel blocker with the demonstrated ability to improve walking ability in patients with multiple sclerosis. We evaluated the in vitro effects of 4-aminopyridine on the human ether-à-go-go-related gene (hERG) channel current, since hERG current inhibition is associated with QT interval prolongation-a precursor to torsade de pointes (TdP). METHODS: 4-Aminopyridine was evaluated in concentrations ranging from 0.1 mM to 30 mM in human embryonic kidney 293 cells stably transfected with the hERG gene; terfenadine 60 nM was used as a positive control. RESULTS AND DISCUSSION: We observed concentration-dependent inhibition of hERG current with 4-aminopyridine doses between 0.3 and 30 mM. The concentration of 3.8 mM resulting in 50% inhibition (IC(50)) is approximately three orders of magnitude higher than expected therapeutic plasma concentrations, suggesting 4-aminopyridine has low potential for prolonging QT interval or inducing TdP.

Structure-activity studies of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes: a novel class of highly potent nicotinic receptor ligands

The potential for nicotinic ligands with affinity for the α4β2 or α7 subtypes to treat such diverse diseases as nicotine addiction, neuropathic pain, and neurodegenerative and cognitive disorders has been exhibited clinically for several compounds while preclinical activity in relevant in vivo models has been demonstrated for many more. For several therapeutic programs, we sought nicotinic ligands with various combinations of affinity and function across both subtypes, with an emphasis on dual α4β2-α7 ligands, to explore the possibility of synergistic effects. We report here the structure-activity relationships (SAR) for a novel series of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes and characterize many of the analogues for activity at multiple nicotinic subtypes.

Validation of a high-throughput, automated electrophysiology platform for the screening of nicotinic agonists and antagonists

High-throughput compound screening using electrophysiology-based assays represents an important tool for biomedical research and drug discovery programs. The recent development and availability of devices capable of performing high-throughput electrophysiology-based screening have brought the need to validate these tools by producing data that are consistent with results obtained with conventional electrophysiological methods. In this study, we compared the response properties of hα3β4 and hα4β2 nicotinic receptors to their endogenous ligand acetylcholine (ACh) using three separate electrophysiology platforms: Dynaflow (low-throughput, manual system), PatchXpress 7000A (medium-throughput automated platform), and IonWorks Barracuda (high-throughput automated platform). We found that despite the differences in methodological approaches between these technologies, the EC(50) values from the ACh dose-response curves were consistent between all three platforms. In addition, we have validated the IonWorks Barracuda for both competitive and uncompetitive inhibition assays by using the competitive nicotinic antagonist dihydro-beta-erythroidin (DHβE) and uncompetitive nicotinic antagonist mecamylamine. Furthermore, we have demonstrated the utility of a custom-written algorithm for generating dose-response curves from multiple extrapolated current metrics that allows for discriminating between competitive and uncompetitive inhibition while maintaining high-throughput capacity. This study provides validation of the consistency of results using low-, medium-, and high-throughput electrophysiology platforms and supports their use for screening nicotinic compounds.

Development and optimization of a high-throughput electrophysiology assay for neuronal alpha4beta2 nicotinic receptors

Historically, the identification of alpha4beta2 nicotinic acetylcholine receptor ligands has been based on high-throughput radioligand binding, rubidium efflux assays and Ca++ flux assays using a fluorometric imaging plate reader (FLIPR). Among other approaches, low-throughput electrophysiological assays in Xenopus oocytes and two channel application "liquid filament" systems for mammalian cells have been commonly used. More recent technical innovations that have been introduced into the field of electrophysiology allow for automated simultaneous multi-channel operation. Here we report the development and optimization of a high-throughput electrophysiological assay for identifying functionally active alpha4beta2 nicotinic receptor ligands using such a system. Characterization of the test system yielded results comparable to those obtained by other investigators using conventional electrophysiological assays. For example, the concentration-response relationships obtained for alpha4beta2 receptor activation by acetylcholine and nicotine were best described by biphasic Hill equations, and the inhibition of alpha4beta2 receptor currents by the nicotinic antagonist dihydro-beta-erythroidine was consistent with previously published results. Functional up-regulation of alpha4beta2 receptors by prolonged exposure to nicotine or lower temperature was also confirmed. Using this methodology we were able to characterize the activation of alpha4beta2 receptors by multiple compounds in a mammalian cell expression system, exemplifying its utility for rapid identification of novel nicotinic ligands within a screening cascade. Our results demonstrate the utility of this electrophysiological tool for the discovery of alpha4beta2 nicotinic acetylcholine receptor ligands with potential applications in numerous clinical indications.

Kurtoxin, a gating modifier of neuronal high- and low-threshold ca channels

Studies of Ca channels expressed in oocytes have identified kurtoxin as a promising tool for functional and structural studies of low-threshold T-type Ca channels. This peptide, isolated from the venomous scorpion Parabuthus transvaalicus, inhibits low-threshold alpha1G and alpha1H Ca channels expressed in oocytes with relatively high potency and high selectivity. Here we report its effects on Ca channel currents, carried by 5 mm Ba(2+) ions, in rat central and peripheral neurons. In thalamic neurons 500 nm kurtoxin inhibited T-type Ca channel currents almost completely (90.2 +/- 2.5% at -85 mV; n = 6). Its selectivity, however, was less than expected because it also reduced the composite high-threshold Ca channel current recorded in these cells (46.1 +/- 6.9% at -30 mV; n = 6). In sympathetic and thalamic neurons, 250-500 nm kurtoxin partially inhibited N-type and L-type Ca channel currents, respectively. It similarly reduced the high-threshold Ca channel current that remains after a blockade of P-type, N-type, and L-type Ca channels in thalamic neurons. In contrast, kurtoxin facilitated steady-state P-type Ba currents in Purkinje neurons (by 34.9 +/- 3.7%; n = 10). In all cases the kurtoxin effect was voltage-dependent and entailed a modification of channel gating. Exposure to kurtoxin slowed current activation kinetics, although its effects on deactivation varied with the channel types. Kurtoxin thus appears as a unique gating-modifier that interacts with different Ca channel types with high affinity. This unusual property and the complex gating modifications it induces may facilitate future studies of gating in voltage-dependent ion channels.

Abstract P273: Increased Inhibition of Potassium Channel Currents by Angiotensin II in Sympathetic Neurons may Contribute to a Sustained Blood Pressure Elevation in (mRen2)27 Rats

It is well established that the increased sympathetic tone may contribute to initiation and progression of various forms of hypertension. Several lines of evidence suggest a link between the renin-angiotensin system and sympathetic nerve activity in hypertension, and the previous studies in animal models demonstrated increased sympathetic output in the presence of Angiotensin II (AngII). To elucidate potential underlying molecular mechanisms of such phenomenon, we compared the effect of AngII on the whole-cell potassium channel currents in superior cervical ganglia (SCG) neurons isolated from hypertensive (mRen2)27 rats with overexpression of renin gene, and control Sprague Dawley® (SD) rats. In both groups, the whole-cell potassium channel currents were identified as rapidly-activating, 4-Aminopyridine-sensitive transient A-type currents, as well as slowly-activating tetraethylammonium-sensitive delayed rectifier currents. When the cell membrane was depolarized to -40, -30 and -20 mV from a holding potential of -80 mV, AngII (100 nM) profoundly inhibited A-type current, but the magnitude of such inhibition was not significantly different between neurons isolated from (mRen2)27 (38.1±6.2%, 47.8±5.7% and 52.1±5.7%; n=11) and SD rats (37.2±4.6%, 44.±4.5% and 46.1±4.8%; n = 13). Delayed rectifier potassium channel currents were isolated by holding cells at -40 mV, which resulted in complete elimination of the transient A-type current. In contrast to transient current, inhibition of the delayed rectifier current by AngII in the range of membrane potentials between +20 and +80 mV was significantly greater (p<0.05) in neurons obtained from (mRen2)27 rats (11.0±3.2% to 25.0±2.9%, n=12) when compared to SD rats (4.7±1.5% to 16.3±2.7%, n = 12). In both groups, inhibition of both channel types was completely abolished by 10 uM Losartan, indicating involvement of AT1 receptors. Our results suggest that in (mRen2)27 hypertensive rats, the increased inhibitory effect of AngII on delayed rectifier potassium channel currents could possibly lead to lowering spike threshold, which, in turn, could elevate sympathetic outflow and lead to sustained blood pressure elevation.

Low-affinity blockade of neuronal N-type Ca channels by the spider toxin omega-agatoxin-IVA

The recognition of neuronal Ca channel diversity has led to considerable efforts to identify useful classification criteria. Here, we revisit the pharmacological definition of P- and Q-type Ca channels, which is based on their respective high and low sensitivity to the spider omega-agatoxin-IVA (omega-Aga-IVA), using whole-cell recordings of the Ca channel currents carried by 5 mM Ba(2+) in isolated rat subthalamic and sympathetic neurons. In subthalamic neurons, omega-Aga-IVA (1 microM) targeted multiple Ca channels. One population was blocked with high potency. These channels carried 50.4 +/- 3.4% (n = 5) of the control current and showed the same inactivation kinetics and voltage-dependent high affinity for omega-Aga-IVA as do prototypic P-type Ca channels. Other Ca channels were targeted with weaker potency. This heterogeneous population contributed to 14.0 +/- 1.7% (n = 5) of the control current. It included N-type Ca channels as well as high-threshold Ca channels that displayed the pharmacological signature of Q-type Ca channels but resembled P-type Ca channels in their gating properties. N-type Ca current block by omega-Aga-IVA (1 microM) was further investigated in sympathetic neurons, which mainly express this Ca channel type. Block was incomplete ( approximately 30% of the control current). Its relief at positive potentials was consistent with omega-Aga-IVA acting as a channel-gating modifier. These effects did not reflect a complete loss of selectivity, because omega-Aga-IVA (1 microM) had no effect on subthalamic Na and K currents or their T- and L-type Ca currents. Our data confirm that omega-Aga-IVA is a selective P-type Ca channel blocker. However, its diminished selectivity in the micromolar range limits its usefulness for functional studies of Q-type Ca channels.

Abstract P344: Increased Expression and Function of Endothelin Receptors in Aorta of (mRen2)27 Hypertensive Rats

Endothelin-1 (ET-1) contributes to various cardiovascular diseases including hypertension. ET-1 is produced in the endothelium and acts via ET A receptors, located in smooth muscle cells, and via ET B receptors, located in both endothelium and smooth muscle cells. Activation of ET A produces vasoconstriction, whereas endothelial ET B activation mediates vasodilation, with previous studies showing that ET-1-mediated vasoconstriction is enhanced in hypertension. We hypothesized that increased ETA-mediated function is present in vasculature of the (mRen2)27 hypertensive rat. Western blotting of total protein extracts from thoracic aorta was used to determine expression of ET A and ET B from Sprague-Dawley (SD n=4) and (mRen2)27 hypertensive (n=5) rats. Specificity of western blot signals for ET A and ET B was assessed by using pre-absorption of primary antibody with the corresponding antigenic peptide and intensity of signals was measured by densitometry (NIH-J Image). Contractile responses to ET-1 (10 -11 -10 -7 M) in intact and denuded aorta were determined by wire myography (Multi Myograph, DMT-USA) in the presence of the ET A blocker BQ123 (10 -6 M) or the ET B blocker BQ788 (10 -6 M). Contraction to ET-1 was expressed as maximal response (ET MAX as %K MAX ) and sensitivity (pD 2 =-Log [EC 50 ]). In aortae from (mRen2)27 rats ET A and ET B receptor expression (48 and 31 kDa bands) was greater relative to aortae of SD rats (p<0.05). ET-1 contraction showed increased sensitivity in (mRen2)27 vs SD aortae (pD 2 , 8.17±0.15 vs 7.76±0.12, p<0.05) with similar ET MAX (157±16 vs 145±6 %K MAX , p>0.05). In intact arteries, blockade of ET B increased ET-1 sensitivity (pD 2 8.4±0.3, p<0.05) in SD without effect on intact arteries from (mRen2)27 rats. In denuded arteries, ETB blockade increased ET MAX only in aortae from (mRen2)27 (205±12 vs 152±5, p<0.05). Thus, increased ET A expression mediates greater ET-1-dependent contraction in vasculature of (mRen2)27 rats. In (mRen2)27 rats, loss of endothelial ET B receptor function in intact arteries may contribute to enhanced constrictor responses to ET-1, whereas increased ET B receptors in smooth muscle cells provide a counterbalancing vasodilation to offset maximal contractile effects of ET-1 in this model of hypertension.